American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Molecular Biomarker Stratification of Adjuvant Treatment for Pancreatic Adenocarcinoma

ASCO 2016 – GI

Safety and efficacy results of a phase 2 trial assessing outcomes of patients with resected pancreatic adenocarcinoma treated with gemcitabine plus cisplatin and stratified by tumor excision repair cross-complementing gene-1 (ERCC1). Read More ›

The Cancer Stem-Cell Inhibitor BBI608 plus Paclitaxel in Advanced Pancreatic Cancer

ASCO 2016 – GI

Results of a phase 1b/2 study of the safety and efficacy of the cancer stem-cell inhibitor BBI608 plus paclitaxel in treating patients with advanced pancreatic cancer. Read More ›

Videos

Targeting the VEGF Axis in Advanced NSCLC

ASCO 2016 – Lung Cancer

Benjamin P. Levy, MD, reviews current and emerging roles for agents that target the VEGF axis in advanced non–small-cell lung cancer and expresses his belief that a lot of work needs to be done to define the optimal space for these drugs. Read More ›

Videos

The Future of Immuno-oncology in Advanced Lung Cancer

ASCO 2016 – Lung Cancer

Videos

Treating Patients with Acquired TKI Resistance

ASCO 2016 – Lung Cancer

Benjamin P. Levy, MD, provides an overview of evolving strategies to manage patients with acquired TKI resistance in advanced non–small-cell lung cancer with a focus on identifying and treating t790m. Read More ›

Results from the REVEL Trial: Exposure-Response Relationship for Ramucirumab plus Docetaxel vs Docetaxel as Second-line Treatment of Metastatic NSCLC

ASCO 2015 – Lung Cancer

American Society of Clinical Oncology (ASCO)

Page 23 of 31